ストックスクリーナーアプリを入手
10.29
0.39%
0.04
アフターアワーズ：
10.29
前日終値:
$10.25
開ける：
$10.2
24時間の取引高:
1,190
Relative Volume:
0.05
時価総額：
$221.21M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+0.98%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$10.20
$10.29
1週間の範囲:
$10.15
$10.29
52週間の値動き範囲:
$10.13
$10.35
Helix Acquisition Corp Iii Stock (HLXC) Company Profile
Compare HLXC vs CCXI, LION, INFQ, XXI, APAD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HLXC
Helix Acquisition Corp Iii
|
10.29 | 220.35M | 0 | 0 | 0 | 0.00 |
|
CCXI
Churchill Capital Corp Xi
|
10.19 | 3.64B | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
8.50 | 2.51B | 3.13B | -174.20M | -111.20M | -0.6937 |
|
INFQ
Infleqtion Inc
|
13.29 | 2.37B | 0 | 0 | 0 | 0.00 |
|
XXI
Twenty One Capital Inc
|
6.15 | 2.17B | 0 | 0 | 0 | 0.00 |
|
APAD
A Paradise Acquisition Corp
|
10.11 | 1.42B | 0 | 0 | 0 | 0.00 |
Helix Acquisition Corp Iii (HLXC) 最新ニュース
Whale Trades: Is MYPSW in a consolidation phaseJuly 2025 Setups & Reliable Intraday Trade Alerts - baoquankhu1.vn
What Wall Street predicts for Plutonian Acquisition Corp. Equity Warrant stock price2025 Sector Review & Safe Capital Growth Trade Ideas - mfd.ru
Will Anixa Biosciences Inc. stock reach all time highs in 2025Weekly Risk Report & Breakout Confirmation Trade Signals - mfd.ru
A | Is Helix Acquisition Corp. II on track to beat earningsMarket Activity Recap & Capital Efficient Trading Techniques - mfd.ru
Aug Opening: Is ONCO being accumulated by smart moneyQuarterly Earnings Report & Community Verified Swing Trade Signals - baoquankhu1.vn
Can AIFER ride the EV waveQuarterly Profit Review & Free Long-Term Investment Growth Plans - mfd.ru
Newsroom - White & Case LLP
Helix Acquisition Corp. III completes $172.5 million IPO and private placement - Investing.com Nigeria
Helix Acquisition Corp. III Completes Initial Public Offering - TradingView
Finance Watch: SPACs Attempt A Comeback As IPO Market Shows Signs Of Life - Citeline News & Insights
Does Helix Acquisition Corp. II have strong fundamentalsJuly 2025 Macro Moves & Advanced Technical Analysis Signals - mfd.ru
With a Thin IPO Calendar, Hedge Funds Are Zeroing In on Biopharma - Institutional Investor
Helix Acquisition prices $150M initial public offering - MSN
Will Helix Acquisition Corp. II stock continue dividend increasesRate Cut & AI Forecast Swing Trade Picks - mfd.ru
Helix Acquisition Corp. III raises $172.5 million in Nasdaq IPO By Investing.com - Investing.com Nigeria
Helix Acquisition Corp III closes $172.5 million IPO By Investing.com - Investing.com South Africa
Helix Acquisition Corp. III closes $172.5 million IPO By Investing.com - Investing.com Australia
Helix Acquisition Corp. III raises $172.5 million in Nasdaq IPO - Investing.com
Helix Acquisition Corp. III closes $172.5 million IPO - Investing.com India
Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares - The Manila Times
SL Green Realty Corp. Announces Date of 2026 Annual Meeting of Stockholders - The Manila Times
Helix Acquisition Corp III closes $172.5 million IPO - Investing.com
White & Case advises Helix Acquisition Corp. III on upsized US$150 million IPO - White & Case LLP
Biotech investor Cormorant secures $150M for another SPAC deal - BioPharma Dive
Insider Buy: Does Unusual Machines Inc align with a passive investing strategyTrade Entry Report & Low Risk Investment Opportunities - baoquankhu1.vn
Helix Acquisition III Raises $150 Million, Targets Healthcare Sector - intellectia.ai
Helix Acquisition Corp. III Prices Upsized $150 Mln IPO - Nasdaq
Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering - The Manila Times
IPO NewsUS IPO Weekly Recap: Equipment rental rises while crypto company crashes in 2-IPO week - renaissancecapital.com
Day One was one of three parties interested in Mersana; Bihua Chen and Cormorant’s third SPAC - Endpoints News
HLXC IPO NewsCormorant's SPAC Helix Acquisition III files for a $125 million IPO, targeting healthcare - renaissancecapital.com
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress - GlobeNewswire
BridgeBio Oncology stock initiated with Outperform rating at Oppenheimer - Investing.com
After Short Stint as a Private Company, BBOT Leaves SPAC Process Ready To Execute - BioSpace
Helix Acquisition Corp. II Completes Merger with BridgeBio - The Globe and Mail
Cantor Fitzgerald initiates BridgeBio Oncology stock with Overweight rating By Investing.com - Investing.com Nigeria
BridgeBio Oncology Therapeutics (Helix Acquisition II): BBOT IPO, SPACBlank check company formed by Cormorant Asset Management targeting healthcare (completed 8/11/2025). - renaissancecapital.com
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition - GlobeNewswire
BridgeBio Oncology Lands Massive $382M SPAC Deal as Top Investors Back Cancer Drug Pipeline - Stock Titan
BBOT Appoints Industry Veteran Uneek Mehra as Chief Financial Officer - Business Wire
BridgeBio Oncology's SPAC Merger Advances: SEC Clears Path for Novel Cancer Drug Development Platform - Stock Titan
Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal - BioSpace
Big Law Firms Wary of SPAC Rebound Seek to Get Paid This Time - Bloomberg Law News
Helix BioPharma (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") Secures Pre-IND Candidates LEUMUNA(TM) and GEMCEDA(TM) in Strategic Acquisition from the Laevoroc Group - TheNewswire
Helix Acquisition Corp. II SEC 10-Q Report - TradingView
Swiss ADC Biotech Takes SPAC Track to NASDAQ - BioSpace
Bay Area VC-funded life sciences companies raised over $5 billion in 2024 - The Business Journals
Checkpoint checks out | ApexOncoClinical Trials news and analysis - Oncology Pipeline
BridgeBio spin-out in SPAC deal to target RAS and PI3Kα malignancies - The Pharma Letter
BridgeBio spinout to go public in SPAC deal with Helix Acquisition Corp. II - MSN
BridgeBio's KRAS-focused cancer spinout backs SPAC as path to Nasdaq - Fierce Biotech
Helix Acquisition Corp Iii (HLXC) 財務データ
Helix Acquisition Corp Iii (HLXC) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.45%
0.30%
大文字化:
|
ボリューム (24 時間):